The global market for Intravascular Stents was estimated at US$28.0 Billion in 2024 and is projected to reach US$40.8 Billion by 2030, growing at a CAGR of 6.5% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Intravascular Stents market.
A significant trend is the transition from bare-metal stents (BMS) to drug-eluting stents (DES) and bioresorbable scaffolds (BRS). DES, which release antiproliferative drugs to prevent restenosis, have largely replaced BMS due to their lower rate of in-stent restenosis and improved long-term outcomes. Bioresorbable stents, although still in early phases of adoption, represent the next generation of vascular intervention technologies by offering temporary scaffolding that dissolves over time. Additionally, advancements in stent delivery systems, coating technologies, and personalized stent sizing are improving procedural success rates and expanding usage across a broader range of vascular conditions.
In neurovascular and peripheral vascular markets, self-expanding stents made of nitinol (nickel-titanium alloy) are gaining traction due to their superelastic properties and ability to adapt to vessel dynamics. Moreover, the integration of imaging technologies such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT) is enhancing stent placement accuracy, ensuring optimal apposition and expansion. Research into nanotechnology-based coatings and gene-eluting stents is also underway, aiming to improve drug delivery efficiency and address limitations like late stent thrombosis. These advances are redefining what's possible in minimally invasive vascular therapy.
Beyond coronary applications, peripheral artery disease (PAD) is a growing area of focus, particularly in aging populations. Self-expanding stents are widely used in the femoropopliteal and iliac arteries, providing long-term patency in vessels subject to high biomechanical stress. Neurovascular stents are also seeing increased deployment in the treatment of cerebral aneurysms and ischemic stroke, especially in conjunction with thrombectomy devices. These expanded use cases across coronary, peripheral, and neurovascular domains are not only increasing total addressable market size but also driving demand for specialized stent designs tailored to different vascular environments.
Another key growth factor is the ongoing R&D investment by medical device companies in next-generation stent platforms. The focus on drug-eluting technology, bioresorbable materials, and AI-integrated stent planning tools is fostering differentiation in an otherwise competitive market. Additionally, the rapid expansion of healthcare access and catheterization labs in Asia-Pacific, Latin America, and the Middle East is contributing to higher procedural volumes. Reimbursement improvements, favorable clinical guidelines, and physician training programs are further supporting adoption in these regions. The convergence of these clinical, technological, and structural drivers is setting the stage for sustained and robust growth in the global intravascular stents market.
Global Intravascular Stents Market - Key Trends & Drivers Summarized
Why Are Intravascular Stents Central to the Evolution of Cardiovascular Treatment?
Intravascular stents have become a cornerstone in the management of coronary artery disease (CAD) and peripheral vascular disorders, offering a minimally invasive alternative to surgical interventions. These small mesh-like tubular devices are used to support blood vessels and maintain arterial patency after angioplasty procedures. With cardiovascular diseases remaining the leading cause of death globally, the demand for effective and durable treatment options is driving the expansion of the intravascular stents market. Technological innovation, growing prevalence of lifestyle diseases, and expanded indications in peripheral and neurovascular applications are among the key contributors to market growth.A significant trend is the transition from bare-metal stents (BMS) to drug-eluting stents (DES) and bioresorbable scaffolds (BRS). DES, which release antiproliferative drugs to prevent restenosis, have largely replaced BMS due to their lower rate of in-stent restenosis and improved long-term outcomes. Bioresorbable stents, although still in early phases of adoption, represent the next generation of vascular intervention technologies by offering temporary scaffolding that dissolves over time. Additionally, advancements in stent delivery systems, coating technologies, and personalized stent sizing are improving procedural success rates and expanding usage across a broader range of vascular conditions.
How Are Innovations in Materials and Design Elevating Clinical Outcomes?
The evolution of intravascular stents is being driven by rapid progress in materials science and device engineering. The use of cobalt-chromium and platinum-chromium alloys in stent construction has enhanced radial strength, visibility under imaging, and flexibility - critical for navigating tortuous vascular anatomies. These materials also allow thinner struts, which reduce vessel trauma and promote faster endothelial healing. In parallel, new-generation DES platforms feature bioabsorbable polymer coatings that degrade after drug release, minimizing long-term inflammation and thrombogenic risk associated with permanent polymers.In neurovascular and peripheral vascular markets, self-expanding stents made of nitinol (nickel-titanium alloy) are gaining traction due to their superelastic properties and ability to adapt to vessel dynamics. Moreover, the integration of imaging technologies such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT) is enhancing stent placement accuracy, ensuring optimal apposition and expansion. Research into nanotechnology-based coatings and gene-eluting stents is also underway, aiming to improve drug delivery efficiency and address limitations like late stent thrombosis. These advances are redefining what's possible in minimally invasive vascular therapy.
Which Therapeutic Segments and Use Cases Are Driving Adoption?
Coronary artery disease remains the largest segment for intravascular stent use, accounting for the bulk of global procedures. The widespread prevalence of ischemic heart disease, combined with the rising incidence of diabetes, obesity, and hypertension, is fueling procedural volumes in both developed and emerging markets. Intravascular stents are increasingly being used in complex lesions, such as bifurcations, chronic total occlusions, and long diffuse lesions, thanks to more flexible and deliverable stent platforms. These innovations allow interventional cardiologists to expand treatment to high-risk patient groups that were previously unsuitable for stenting.Beyond coronary applications, peripheral artery disease (PAD) is a growing area of focus, particularly in aging populations. Self-expanding stents are widely used in the femoropopliteal and iliac arteries, providing long-term patency in vessels subject to high biomechanical stress. Neurovascular stents are also seeing increased deployment in the treatment of cerebral aneurysms and ischemic stroke, especially in conjunction with thrombectomy devices. These expanded use cases across coronary, peripheral, and neurovascular domains are not only increasing total addressable market size but also driving demand for specialized stent designs tailored to different vascular environments.
What's Fueling the Market Growth Across Clinical, Technological, and Regional Dimensions?
The growth in the intravascular stents market is driven by several factors related to clinical demand, innovation pipelines, and expanding healthcare infrastructure. One of the most significant drivers is the aging global population and the associated rise in cardiovascular and peripheral vascular conditions. This demographic shift is creating sustained demand for less invasive, high-efficacy treatment solutions like stents, particularly in outpatient and ambulatory care settings. Concurrently, the global healthcare industry is moving toward value-based care, favoring interventions that minimize hospital stays, reduce complication rates, and improve long-term outcomes - attributes that intravascular stents are well-positioned to deliver.Another key growth factor is the ongoing R&D investment by medical device companies in next-generation stent platforms. The focus on drug-eluting technology, bioresorbable materials, and AI-integrated stent planning tools is fostering differentiation in an otherwise competitive market. Additionally, the rapid expansion of healthcare access and catheterization labs in Asia-Pacific, Latin America, and the Middle East is contributing to higher procedural volumes. Reimbursement improvements, favorable clinical guidelines, and physician training programs are further supporting adoption in these regions. The convergence of these clinical, technological, and structural drivers is setting the stage for sustained and robust growth in the global intravascular stents market.
Scope of Study:
The report analyzes the Intravascular Stents market in terms of units by the following Segments, and Geographic Regions/Countries:- Segments: Type (Drug Eluting Stents, Bare Metal Stents, Bioabsorbable Stents); Delivery Mode (Self-expanding Stents, Balloon-expandable Stents); Product Type (Coronary Stents, Peripheral Stents, Neurovascular Stents); End-Use (Hospitals & Cardiac Centers, Ambulatory Surgery Centers, Others)
- Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Drug Eluting Stents segment, which is expected to reach US$26.5 Billion by 2030 with a CAGR of a 6.6%. The Bare Metal Stents segment is also set to grow at 6.4% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $7.6 Billion in 2024, and China, forecasted to grow at an impressive 10.2% CAGR to reach $8.4 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Intravascular Stents Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Intravascular Stents Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Intravascular Stents Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Abbott Laboratories, Alvimedica, Asahi Intecc Co., Ltd., B. Braun Melsungen AG, Biosensors International Group and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the 36 companies featured in this Intravascular Stents market report include:
- Abbott Laboratories
- Alvimedica
- Asahi Intecc Co., Ltd.
- B. Braun Melsungen AG
- Biosensors International Group
- BIOTRONIK SE & Co. KG
- Boston Scientific Corporation
- C. R. Bard (now part of BD)
- Cardinal Health (Cordis)
- Cook Medical
- Johnson & Johnson
- Medinol Ltd.
- Medtronic plc
- MicroPort Scientific Corporation
- Nipro Corporation
- OrbusNeich Medical
- STENTYS SA
- Terumo Corporation
- Terumo Interventional Systems
This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:
- Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
- Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
- Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
- Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
- Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
- Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
- Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- Alvimedica
- Asahi Intecc Co., Ltd.
- B. Braun Melsungen AG
- Biosensors International Group
- BIOTRONIK SE & Co. KG
- Boston Scientific Corporation
- C. R. Bard (now part of BD)
- Cardinal Health (Cordis)
- Cook Medical
- Johnson & Johnson
- Medinol Ltd.
- Medtronic plc
- MicroPort Scientific Corporation
- Nipro Corporation
- OrbusNeich Medical
- STENTYS SA
- Terumo Corporation
- Terumo Interventional Systems
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 462 |
Published | June 2025 |
Forecast Period | 2024 - 2030 |
Estimated Market Value ( USD | $ 28 Billion |
Forecasted Market Value ( USD | $ 40.8 Billion |
Compound Annual Growth Rate | 6.5% |
Regions Covered | Global |